Study finds elevated NT-proBNP levels in T2 #Diabetes patients indicate worse #HeartFailure and kidney outcomes, regardless of prior HF history. Higher risk with HF diagnosis. #CardiovascularRisk #CANVAStrial
Baim faculty James Januzzi Jr MD Javed Butler
doi.org/10.1016/j.card…

Day 1 of #globaltrialssummit starts in 6 hours.... All the major leaders present live. Register at events.hubilo.com/global-trials-… #GTS2024 . Those registered can view all for 12 months.

We Are Chasing Impact, Not Impact Factor—my video w/my vision for #JACC . I was frustrated with the peer-reviewed journal establishment, and now I am part of it. So…can we create author-centricity, and high-value for society. JACC Journals youtube.com/watch?v=bbHSR6…

In #HeartFailure patients irrespective of EF, the KCCQ-TSS shows rapid improvement within the initial treatment period following #canagliflozin treatment. These findings are vital for treatment guidance and future study designs. bit.ly/3Q4A6uZ

#JACCHF #SGLT2i

The pipeline of non-steroidal mineralocorticoid antagonists for patients with heart failure (in clinical trials) is rich, and growing.

I hope you can join and participate in this opportunity to innovate for our patients.

Mikhail Kosiborod Alexandre Mebazaa
James Januzzi Jr MD Javed Butler

#cardiology #ACC24 #cardioX #CardioTwitter

Patients with acute myocardial infarction are at a high risk of #heartfailure & death.

Listen to Javed Butler, MD, MPH, MBA, Javed Butler & Sun Moon Kim, MD, FACC, Sun Moon Kim, MD FACC FSCAI discuss the results of the EMPACT-MI trial on #ACCEL Lite podcast: bit.ly/3J9M4j4

Calling all the HFA Young members 📣
🌟Register now for a memorable evening of networking on the Lisbon dock’s during the HF Congress #HeartFailure2024
Seats limited myesc.escardio.org/s/event-regist…
🆓 for HFA members
Antonio Cannata' Jozine ter Maaten Cornelia Margineanu Alberto Esteban Henry Han

Assistez à la Conférence Servier Canada sur l’insuffisance cardiaque de l’Institut de cardiologie avec Dr Javed Butler (Javed Butler).
🗓️ Lundi 15 avril
⏰ 12 h HAE

« Where Are We With Heart Failure”»

👉 Inscrivez-vous : ow.ly/hYuA50RelFe
UOHI Research Services Heart Institute FDN

But is it safe to introduce an SGLT2i in hospitalised patients ⁉️

EMPACT-MI #ACC24

‘Acute MI setting, IV contrast, procedures & potentially simultaneous new initiation of RAASi, MRA & SGLT2i together … and there were NO safety concerns at all’ Javed Butler

🫳🏼
🎤

Recharging after a phenomenal #ACC2024

Sharing some of my thoughts on EMPACT-MI from the deep dive session with Javed Butler

Adrian “WE NEED RCTS!” Hernandez Schuyler Jones Duke Clinical Research Institute Duke Heart Anu Lala-Trindade Josephine Harrington, MD Dr. Martha Gulati ♥️🫀❤️‍🩹🇨🇦

Use of the #SGLT2 empagliflozin following a heart attack did not show a significant benefit in reducing overall #HeartFailure hospitalizations or death from any cause, according to a new study presented by Dr. @javedbutler1 at #ACC24 . bit.ly/3xkPYmm Baylor Scott & White Health

New #ACC24 #SimPub in Journal of Cardiac Failure led by ⭐️Duke IM Residency Hubert B Haywood

What proportion of patients hospitalized for #HF are potentially eligible for a #HospitalAtHome strategy?

Javed Butler Gregg Fonarow MD Duke Clinical Research Institute Duke IM Chief Residents Duke Cardiology Fellows

onlinejcf.com/article/S1071-…

Beautiful deep dive discussion on #EMPACT_MI by Robert Mentz, MD #ACC24

So…would you use SGLT2i post MI?

Javed Butler responds:
If indication (HF, DM, CKD) go ahead and get started!
If a revascularized STEMI pt & no other major issue, probably ok not to start in acute setting!

EMPACT-MI - #ACC24

Does Empagliflozin ⬇️ ⏰ till first HF hospitalisation & all cause ☠️ ?

🔑 🚫 benefit with co-primary endpoint, but BIG ⬇️ in HF 🏥 & HF adverse events with secondary analysis

#MedTwitter #MedX #MedEd #FOAMed #cardiotwitter Javed Butler Shelley Zieroth

🔥 THIS JUST IN 🔥

⁦Javed Butler⁩ ⁦Mikhail Kosiborod⁩

Semaglutide versus placebo in people with obesity-related heart failure with preserved ejection fraction: a pooled analysis of the STEP-HFpEF and STEP-HFpEF DM randomised trials - The Lancet thelancet.com/journals/lance…

HF Events

Semaglutide 1.3 vs placebo 4.9 per 100 patient years

Odds ratio 0.27 (95% CI 0.12-0.56) p=0.0004

Semaglutide versus placebo in people with obesity-related heart failure with preserved ejection fraction: a pooled analysis of the STEP-HFpEF and STEP-HFpEF DM randomised trials - The Lancet thelancet.com/journals/lance…

Javed Butler The Lancet #ACC2024

Steve Greene Andrew J Sauer MD AHA Science Clyde Yancy, MD, MSc Javed Butler Duke Clinical Research Institute AHA Research Duke Cardiology Fellows Harriette Van Spall, MD MPH Shelley Zieroth Ankeet S. Bhatt, MD, MBA Vishal Rao Shahzeb Khan Mikhail Kosiborod Anu Lala-Trindade American Heart Association All participating regions demonstrated substantial improvement in use of quadruple GDMT by hospital discharge and at 30 days

Implementation of quadruple GDMT is feasible, scalable, and sustainable on a national scale

#ACC24 #SimPub in Circulation by Sid M. Patel & #SMARTc investigators

Massive effort evaluating 78,607 patients across 11 late-phase trials in diabetes, CKD, & HF providing definitive evidence of the effects of #SGLT2i on #MACE

ahajournals.org/doi/10.1161/CI…